Espresa launches Specialty Care Accounts to control rising GLP-1 drug costs

On 2026-04-21, Espresa announced the launch of Specialty Care Accounts, a new employer-defined benefits product. The platform is designed to cap employer exposure to high-cost specialty care, including GLP-1 weight-loss drugs, hormone therapy, and specialty mental health services. The company said the model gives employers predictable annual allowances instead of open-ended medical claims exposure.